Cargando…

Author's Reply: Why Did the Patient Not Show Any Neurological Symptoms on the Day of the Higher Serum Concentration of Ceftriaxone?

Detalles Bibliográficos
Autores principales:	Suzuki, Soichiro, Naito, Shotaro, Uchida, Shinichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2019
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949443/ https://www.ncbi.nlm.nih.gov/pubmed/31366808 http://dx.doi.org/10.2169/internalmedicine.3454-19

Ejemplares similares

Why Did the Patient Not Show Any Neurological Symptoms on the Day of the Higher Serum Concentration of Ceftriaxone?
por: Fukuchi, Takahiko, et al.
Publicado: (2019)

Encephalopathy Induced by High Plasma and Cerebrospinal Fluid Ceftriaxone Concentrations in a Hemodialysis Patient
por: Suzuki, Soichiro, et al.
Publicado: (2019)

The Author's Reply to “Did This Cryptococcosis Patient Have HIV Coinfection?”
por: Sato, Shuku
Publicado: (2019)

HCQ prophylaxis in COVID-19 did not show any QTc prolongation in Healthcare workers
por: Jha, Sujeet, et al.
Publicado: (2021)

Serious Neurological Adverse Events of Ceftriaxone
por: Lacroix, Clémence, et al.
Publicado: (2021)

The Authors' Reply
por: Goto, Norihiko, et al.
Publicado: (2018)

Why Did He Say This?
Publicado: (1898)

Reply to Yan and Muller, “Remdesivir for COVID-19: Why Not Dose Higher?”
por: Juneja, Kavita, et al.
Publicado: (2021)

Guided imagery relaxation therapy on preoperative anxiety: why did the authors omit pain data?
por: Gray, Richard, et al.
Publicado: (2020)

Why Did the FDA Approve These Advertisements?
por: Oaks, David
Publicado: (2006)

Why Did America Declare War?
Publicado: (1918)

Why Most Published Research Findings Are False: Author's Reply to Goodman and Greenland
por: Ioannidis, John P. A
Publicado: (2007)

Why the application of IVIG might be beneficial in patients with COVID-19 – Authors' reply
por: Mazeraud, Aurélien, et al.
Publicado: (2022)

Why has the incidence of heart failure decreased by half in Türkiye?—Authors’ reply
por: Çelik, Ahmet, et al.
Publicado: (2023)

Repurposing of the β-Lactam Antibiotic, Ceftriaxone for Neurological Disorders: A Review
por: Yimer, Ebrahim M., et al.
Publicado: (2019)

Reply to: When did mammoths go extinct?
por: Wang, Yucheng, et al.
Publicado: (2022)

Provisional case definitions for COVID-19-associated neurological disease – Authors' reply
por: Solomon, Tom, et al.
Publicado: (2020)

Why Did the Meerkat Cross the Road? Flexible Adaptation of Phylogenetically-Old Behavioural Strategies to Modern-Day Threats
por: Perony, Nicolas, et al.
Publicado: (2013)

Hereford and Cholera — Why Did We Escape It?
por: Ross, John
Publicado: (1990)

Authors′ reply
por: Grover, A K
Publicado: (2008)

Authors' Reply
por: Salas, Antonio, et al.
Publicado: (2006)

Author's Reply
por: Krleža-Jerić, Karmela
Publicado: (2006)

Authors' Reply
por: Bush, Eliot C, et al.
Publicado: (2006)

Author's Reply
por: Kaeberlein, Matt, et al.
Publicado: (2006)

Authors' Reply
por: Stafford, Randall S, et al.
Publicado: (2006)

Authors' Reply
por: Lacasse, Jeffrey R, et al.
Publicado: (2006)

Authors' Reply
por: Lyssenko, Valeriya, et al.
Publicado: (2006)

Author's Reply
por: Ioannidis, John P. A
Publicado: (2005)

Author's Reply
por: Attaran, Amir
Publicado: (2005)

Authors' Reply
por: Auvert, Bertran, et al.
Publicado: (2006)

Authors' Reply
por: van Nimwegen, Erik, et al.
Publicado: (2006)

Authors' Reply
por: Gandy, Sam, et al.
Publicado: (2005)

Author's Reply
por: Gatz, Margaret
Publicado: (2005)

Authors' Reply
por: Stuge, Tor B, et al.
Publicado: (2005)

Authors' Reply
por: Stoneking, Mark, et al.
Publicado: (2005)

Author's Reply
por: Ebrahim, Shah
Publicado: (2005)

Authors' Reply
por: Hotez, Peter J, et al.
Publicado: (2006)

Author's Reply
por: Kravitz, Richard L
Publicado: (2006)

Authors' Reply
por: Mackie, Jocelyn E, et al.
Publicado: (2006)

Authors' Reply
por: Wendler, David, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_gsnqif57rs2n26sidneb711c8u